Statements (66)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:monoclonal_antibody
|
| gptkbp:bfsLayer |
6
|
| gptkbp:bfsParent |
gptkb:EMD_Serono
gptkb:Neratinib gptkb:Chugai_Pharmaceutical |
| gptkbp:activities |
inhibits HE R2 receptor signaling
|
| gptkbp:appointed_by |
gptkb:docetaxel
gptkb:paclitaxel gptkb:pertuzumab gptkb:carboplatin intravenous infusion outpatient settings advanced breast cancer HE R2-positive esophageal cancer HE R2-positive gastric cancer early breast cancer recurrent breast cancer |
| gptkbp:approves |
gptkb:1998
gptkb:FDA |
| gptkbp:associated_with |
improved survival rates
|
| gptkbp:can_be_used_with |
chemotherapy
|
| gptkbp:caused_by |
hypersensitivity reactions
|
| gptkbp:clinical_trial |
Phase III
|
| gptkbp:combatants |
high affinity for HE R2
|
| gptkbp:contraindication |
pregnancy
severe heart failure |
| gptkbp:developed_by |
gptkb:Genentech
|
| gptkbp:established |
tumor growth
|
| https://www.w3.org/2000/01/rdf-schema#label |
Trastuzumab
|
| gptkbp:indication |
gptkb:healthcare_organization
|
| gptkbp:interacts_with |
immune system
|
| gptkbp:is_associated_with |
reduced recurrence rates
|
| gptkbp:is_available_on |
biosimilar products
|
| gptkbp:is_considered |
targeted therapy
standard of care life-saving therapy |
| gptkbp:is_evaluated_by |
clinical trials
safety and efficacy |
| gptkbp:is_monitored_by |
cardiac function
|
| gptkbp:is_part_of |
combination therapy
cancer treatment guidelines multimodal treatment approach breast cancer treatment protocols HE R2-targeted therapy |
| gptkbp:is_subject_to |
patent protection
|
| gptkbp:is_used_for |
treatment of HE R2-positive breast cancer
|
| gptkbp:is_used_in |
gptkb:municipality
palliative care research studies clinical practice |
| gptkbp:lifespan |
approximately 5-8 days
|
| gptkbp:manager |
subcutaneous
|
| gptkbp:marketed_as |
gptkb:Herceptin
|
| gptkbp:produced_by |
Chinese hamster ovary cells
|
| gptkbp:side_effect |
fatigue
nausea diarrhea infusion reactions cardiotoxicity |
| gptkbp:suitable_for |
HE R2-negative tumors
|
| gptkbp:targets |
HE R2 protein
|
| gptkbp:used_in |
adjuvant therapy
neoadjuvant therapy metastatic breast cancer early-stage breast cancer |
| gptkbp:weight |
148 k Da
|